Bioventus (BVS) Stock Price, News & Analysis

Company Overview

Bioventus Inc. (NASDAQ:BVS) is a medical device and biologics company focused on products that support healing and improve function for patients with musculoskeletal conditions. Its portfolio is designed for use in orthopedics, sports medicine, rehabilitation and related specialties.

The company’s products include bone-healing systems, such as EXOGEN, which uses ultrasound technology to support fracture healing, as well as osteoarthritis treatments including injectable hyaluronic acid products such as DUROLANE and GELSYN-3. Bioventus also offers surgical solutions, including bone graft substitutes and other biologic products intended to support bone repair and regeneration.

Bioventus serves healthcare providers and patients in the United States and international markets through a combination of direct sales, distributors and other commercial partners. The company was established in 2011 as a former division of Smith & Nephew and became a publicly traded company in 2021. Its corporate headquarters are in Durham, North Carolina.

Key Stats

• Today's Range: $12.34 to $12.99
• 50-Day Range: $11.48 to $15.26
• 52-Week Range: $6.26 to $15.89
• Volume: 828,232 shs
• Average Volume: 499,649 shs
• Market Capitalization: $1.09 billion
• P/E Ratio: 16.77
• Dividend Yield: N/A
• Price Target: $16.80
• Consensus Rating: Moderate Buy

Bioventus Stock Analysis - MarketRank™

Bioventus scored higher than 73% of companies evaluated by MarketBeat, and ranked 172nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bioventus has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Bioventus has a consensus price target of $16.80, representing about 30.1% upside from its current price of $12.91.

Amount of Analyst Coverage

Bioventus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.66%

Earnings Growth

Earnings for Bioventus are expected to grow by 12.66% in the coming year, from $0.79 to $0.89 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bioventus is 16.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bioventus is 16.77, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.79.

Price to Earnings Growth Ratio

Bioventus has a PEG Ratio of 1.61. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bioventus has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.62% of the float of Bioventus has been sold short.

Short Interest Ratio / Days to Cover

Bioventus has a short interest ratio ("days to cover") of 4.65.

Change versus previous month

Short interest in Bioventus has recently increased by 10.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bioventus does not currently pay a dividend.

Dividend Growth

Bioventus does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 5 people have searched for BVS on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Bioventus to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bioventus insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.50% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BVS
• Previous Symbol: NASDAQ:BVS
• CIK: 1665988
• Web: bioventus.com
• Phone: (919) 474-6700
• Fax: N/A
• Employees: 950
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Bioventus: $16.80
• High Price Target: $19.00
• Low Price Target: $14.00
• Potential Upside/Downside: +30.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.77
• Trailing P/E Ratio: 16.77
• Forward P/E Ratio: 16.34
• P/E Growth: 1.61
• Net Income: $22.73 million
• Net Margins: 9.36%
• Pretax Margin: 6.64%
• Return on Equity: 28.08%
• Return on Assets: 9.82%

Debt

• Debt-to-Equity Ratio: 0.83
• Current Ratio: 1.69
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $581.85 million
• Price / Sales: 1.87
• Cash Flow: $1.30 per share
• Price / Cash Flow: 9.90
• Book Value: $2.76 per share
• Price / Book: 4.68

Miscellaneous

• Outstanding Shares: 84,092,000
• Free Float: 55,921,000
• Market Cap: $1.09 billion
• Optionable: N/A
• Beta: 0.65